# Executive Business Case: Clinical Trial Feasibility & Market Competition Intelligence

## 1. Executive Summary
- **Business Purpose:** Transforms public global clinical trial registries (ClinicalTrials.gov) into a time-series feasibility intelligence asset that scores competitive trial congestion, site saturation, and geographical feasibility before trial launch.
- **Target Stakeholders:** VP of Clinical Operations, Directors of Feasibility & Study Planning, Chief Medical Officer, CRO Business Development.
- **Key Business Impact:** Mitigates the risk of protocol enrollment delays that cost pharmaceutical sponsors `$600,000` to `$8,000,000` per day in operational burn and lost patent exclusivity.

---

## 2. The Business Problem & Market Context

### The Clinical Enrollment Crisis
- Over **80% of clinical trials** fail to enroll their target patient cohort within the planned timeline.
- **50% of trial sites** enroll zero or only one patient due to over-competition and poor site selection.
- Trial delays directly burn capital and postpone commercial market entry:

```
Daily Cost of Clinical Trial Delays:
Operational Site & Staff Burn Rate: ~$30,000 to $100,000 / day
Lost Patent Exclusivity Value (Blockbuster Drug): ~$1,000,000 to $8,000,000 / day
Average Trial Delay (6 Months) Financial Exposure: >$10,000,000 to $150,000,000
```

### The Planning Blindspot
Sponsors traditionally rely on static, historical investigator surveys that quickly become obsolete. They lack a continuous, automated market-wide surveillance system to monitor competitor trial starts, phase transitions, and site recruitment congestion in real time.

---

## 3. Operational & Strategic Value

| Feature / Module | Technical Mechanism | Tangible Clinical Operations Value |
| :--- | :--- | :--- |
| **Market Congestion Scoring** | dbt marts calculating weighted trial density per condition, phase, and geographic country/state. | Pinpoints saturated therapeutic regions to prevent launching duplicate trials in overburdened site networks. |
| **Weekly Snapshot Diffing** | Effective-dated tracking of status transitions (e.g., `Recruiting` → `Terminated` or `Active, not recruiting`). | Detects early signals of competitor trial terminations or recruitment headwinds. |
| **Feasibility Review Dashboard** | Interactive Streamlit workspace with granular filtering by intervention, condition taxonomy, and phase. | Empowers clinical study teams to model site-feasibility scenarios in minutes rather than weeks. |

---

## 4. Executive Decision-Making Framework

```
Phase II/III Trial Feasibility Assessment Workflow:
[Therapeutic Area & Inclusion Filter]
               ↓
[Compute Regional Site Density Index]
               ↓
├── If Density Index > Threshold (Congested) → Pivot site mix to emerging secondary regions
└── If Density Index ≤ Threshold (Optimal)   → Proceed with targeted investigator outreach
```

---

## 5. Data Governance & Regulatory Disclaimer
- **Public-Registry Planning Signals:** All pipeline metrics represent structured public registry signals for operational planning, not clinical decision support or medical outcome forecasts.
- **Reproducible Pipeline:** Powered by DuckDB, dbt tests, and automated GitHub Actions CI.
